Business Context and Reporting Period
Company: SeaStar Medical Holding Corporation (Nasdaq: ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2024
Reporting Period Impact: The filing announces a restatement of audited financial statements for the fiscal year ended December 31, 2022, and unaudited interim statements for the quarters ended March 31, June 30, and September 30, 2023.
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on the accounting methodology changes requiring a restatement of previously issued financial statements.
Material Changes and Restatement Details
The Audit Committee determined that a restatement is necessary due to errors in the accounting treatment of two specific instruments:
- Classification of Warrants: Private placement and PIPE warrants were originally classified as equity. They must be reclassified as liabilities under ASC 815-40. These warrants require remeasurement at each reporting date, with fair value changes recognized in earnings.
- Prepaid Forward Purchase Agreements: Originally accounted for as net assets, these must be reclassified as hybrid instruments. This includes a subscription receivable (equity) and an embedded derivative liability. The derivative liability requires remeasurement at each reporting date with changes in fair value recognized in earnings.
The restatement impacts non-cash items in the Consolidated Balance Sheets, Statements of Operations, Changes in Stockholders' Deficit, and Cash Flows for the periods listed above.
Outlook, Risks, and Management Commentary
Internal Controls: The Company expects to disclose a material weakness in the design and operation of internal controls over financial reporting in its upcoming Form 10-K. A remediation plan will be detailed in that filing.
Accounting Firm Transition: Discussions regarding the restatement were held with the new independent auditor, WithumSmith+Brown, PC (appointed November 28, 2023), and the prior auditor, Armanino LLP.
Risk Factors: The filing reiterates standard risks for the company, including:
- Failure to obtain regulatory approval for SCD product candidates.
- Inability to raise sufficient capital for operations and clinical trials.
- Delays in product development or commercialization.
- Failure to achieve or sustain profitability.
- Inability to access funding under existing equity lines or forward purchase agreements.
Investor Verification Checklist
- Verify the magnitude of the financial impact once the amended and restated financial statements are filed.
- Review the upcoming Form 10-K for the specific details of the material weakness in internal controls and the proposed remediation plan.
- Monitor the Company's ability to access capital given the restatement and potential market reaction.
- Confirm the timeline for the release of the restated financial statements for the 2022 and 2023 periods.